The U.S. Centers for Medicare & Medicaid Services, or CMS, said it is considering ways to bring "greater transparency" to the Medicare drug pricing negotiation program mandated under the Inflation ...

An increased prevalence of chronic kidney disease is expected to fuel growth in the nulojix market. The rise in chronic kidney disease is a long-term condition where the kidneys gradually lose their ...

Chiesi, the international research-focused biopharmaceutical Group, announces the appointment of three new independent Non-Executive Directors (NEDs) to its Board: Roch Doliveux, Paolo Pucci and ...

Liaohai “Leo” Chen, a research scientist who oversaw a $20 million surgical robotics training facility while at the ...

Tech stocks have always been a playground for dreamers and believers, but the recent breakout of the Chinese artificial ...

The layoffs follow an announcement in early January that I-Mab will re-prioritize resources to focus on advancing a CLDN18.2 ...

President Donald Trump’s Medicare agency is seeking to bring more transparency to the US government’s drug price negotiation ...

The growing demand for fast and effective sinusitis treatments is expected to drive further innovations in pharmaceuticals and medical devices. Increasing awareness, advancements in drug formulations ...

The U.S. Centers for Medicare and Medicaid Services has named Novo Nordisk’s Wegovy, Ozempic and Rybelsus as part of the ...

As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...

Mab’s pipeline pivot had a sting in the tail. Weeks after shifting its focus, the biotech said Wednesday that it has reduced ...

Over the last three months, we've seen significantly more insider buying, than insider selling, at Bristol-Myers Squibb.